Sparsentan Use Could Lower Risk of Kidney Failure, Death in FSGS

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

Related Keywords

United States ,Massachusetts ,American ,Michelle Rheault ,Julier Ingelfinger ,University Of Minnesota Michelle Rheault ,American Society Of Nephrology Kidney Week ,University Of Minnesota ,American Society ,Nephrology Kidney Week ,Travere Therapeutics ,New England Journal ,Pediatric Nephrology ,Massachusetts General Hospital ,Focal Segmental ,Asn 23 ,Kidney Week ,Fsgs Treatments ,Sparsentan ,